Skip to main content

Table 1 Baseline characteristics between patients with NACE and non-NACE

From: Prognostic of different glomerular filtration rate formulas in patients receiving percutaneous coronary intervention: insights from a multicenter observational cohort

Characteristic Total
(n = 2159)
non-NACE
(n = 2120)
NACE
(n = 39)
P value
Age (year) 64.23 ± 10.25 64.12 ± 10.26 70.15 ± 7.75 < 0.001
 Age ≥ 65 years 1086 (50.3%) 1058 (49.9%) 28 (71.8%) 0.007
Weight (kg) 66.49 ± 12.14 66.55 ± 11.93 63.25 ± 20.55 0.323
Male sex 1591 (73.7%) 1569 (74.0%) 22 (56.4%) 0.013
Smoking 601 (27.8%) 590 (27.8%) 11 (28.2%) 0.959
CHF 274 (12.7%) 264 (12.5%) 10 (25.6%) 0.014
CKD 382 (17.7%) 370 (17.5%) 12 (30.8%) 0.031
MI history 342 (15.8%) 334 (15.8%) 8 (20.5%) 0.420
Prior PCI 400 (18.5%) 397 (18.7%) 3 (7.7%) 0.079
Prior CABG 22 (1.0%) 22 (1.0%) 0 (0.0%) 0.523
Stroke 160 (7.4%) 158 (7.5%) 2 (5.1%) 0.583
Atrial fibrillation 71 (3.3%) 70 (3.3%) 1 (2.6%) 0.798
Hypertension 1490 (69.0%) 1463 (69.0%) 27 (69.2%) 0.976
Diabetes mellitus 715 (33.1%) 698 (32.9%) 17 (43.6%) 0.301
Hyperlipemia 473 (21.9%) 462 (21.8%) 11 (28.2%) 0.337
Clopigrel or Ticagrelor 2139 (99.1%) 2100 (99.1%) 39 (100.0%) 0.553
 Clopigrel/Ticagrelor loading 1422 (65.9%) 1398 (65.9%) 24 (61.5%) 0.565
Aspirin 2105 (97.6%) 2067 (97.6%) 38 (97.4%) 0.934
 Aspirin loading 554 (25.7%) 534 (25.2%) 20 (51.3%) < 0.001
Cilostazol 52 (2.4%) 50 (2.4%) 1 (2.6%) 0.007
Statin 2123 (98.5%) 2085 (98.4%) 38 (100.0%) 0.438
DAPT 2092 (97.0%) 2054 (97.0%) 38 (97.4%) 0.881
Warfarin 13 (0.6%) 13 (0.6%) 0 (0.0%) 0.624
ACEI/ARB 1650 (76.5%) 1622 (76.5%) 28 (71.8%) 0.488
CCB 544 (25.2%) 527 (24.9%) 17 (43.6%) 0.008
Nitric acid merged 1294 (60.0%) 1262 (59.6%) 32 (82.1%) 0.004
Beta blockers 1804 (83.6%) 1770 (83.5%) 34 (87.2%) 0.542
Tirofiban 204 (9.4%) 192 (9.1%) 12 (30.8%) < 0.001
Number of stents 2 (1 ~ 3) 2 (1 ~ 3) 2 (1 ~ 3) 0.047
Total length of stents (mm) 39 (24 ~ 66) 38 (24 ~ 65) 51 (33 ~ 84) 0.023
Diagnosis     0.472
 Unstable angina 1227 (56.9%) 1207 (57.0%) 20 (51.3%)  
 NSTEMI 928 (43.1%) 909 (43.0%) 19 (48.7%)  
Cys-c (mg/L) 1.20 ± 1.77 1.19 ± 1.78 1.44 ± 0.98 0.138
Creatinine (μmol/l) 94.14 ± 69.35 93.47 ± 66.16 130.28 ± 166.34 0.176
Estimated GFR (ml/min/1.73 m2)
 c-aGFR 86.98 ± 29.53 87.19 ± 29.45 75.18 ± 32.21 0.012
 CG 73.03 ± 27.93 73.31 ± 27.88 57.71 ± 26.58 0.001
 CKD-EPIcr 77.18 ± 21.52 77.40 ± 21.41 65.37 ± 24.65 0.001
 CKD-EPICys-C 71.72 ± 26.44 71.91 ± 26.36 61.23 ± 29.33 0.012
 CKD-EPIcr-Cys-C 65.70 ± 21.18 65.90 ± 21.10 55.16 ± 23.13 0.002
  1. CHF chronic heart failure, CKD chronic kidney disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, DAPT dual antiplatelet therapy, ACEI/ARB aldosterone receptor inhibitors and aldosterone receptor antagonist, CCB calcium channel blocker, NSTEMI non-ST segment elevation myocardial infarction, eGFR estimated glomerular filtration rate